{"transactions":[{"id":707737,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true}}],"security":"Stock Options (right to buy)","published_at":"2026-07-18T01:50:37.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":16610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant."}],"balance_after":16610,"derivative":{"exercise_price":0.5149,"expiration_date":"2036-07-16","underlying":"Common Stock","underlying_shares":16610},"source":{"system":"sec-edgar","filing":"0001437749-26-023810","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774926023810/rdgdoc.xml","form_type":"4"}},{"id":707736,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-07-18T01:50:37.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":8315,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant."}],"balance_after":87115,"source":{"system":"sec-edgar","filing":"0001437749-26-023810","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774926023810/rdgdoc.xml","form_type":"4"}},{"id":796447,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2026-05-02T00:55:09.000Z","date":"2026-04-23","kind":"grant","planned":false,"acquired":true,"shares":157400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in equal installments on each of the first three anniversaries of the grant date, subject to the reporting person's continuing service on the Board."}],"balance_after":157400,"derivative":{"exercise_price":0.7399,"expiration_date":"2036-04-23","underlying":"Common Stock","underlying_shares":157400},"source":{"system":"sec-edgar","filing":"0001437749-26-014528","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774926014528/rdgdoc.xml","form_type":"4"}},{"id":796446,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-02T00:55:09.000Z","date":"2026-04-23","kind":"grant","planned":false,"acquired":true,"shares":78800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest in equal installments on each of the first three anniversaries of the grant date, subject to the reporting person's continuing service on the Board of Directors (the \"Board\")."}],"balance_after":78800,"source":{"system":"sec-edgar","filing":"0001437749-26-014528","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774926014528/rdgdoc.xml","form_type":"4"}},{"id":1640762,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2024-02-15T18:00:26.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":6200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date."}],"balance_after":6200,"derivative":{"exercise_price":9.18,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":6200},"source":{"system":"sec-edgar","filing":"0001209191-24-003413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919124003413/doc4.xml","form_type":"4"}},{"id":1640761,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2024-02-15T18:00:26.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":28400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date."}],"balance_after":28400,"derivative":{"exercise_price":9.18,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":28400},"source":{"system":"sec-edgar","filing":"0001209191-24-003413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919124003413/doc4.xml","form_type":"4"}},{"id":1685352,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-05T16:00:17.000Z","date":"2024-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":4485,"price":0.4961,"value":2225.0085,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":15426,"source":{"system":"sec-edgar","filing":"0001209191-24-000970","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919124000970/doc4.xml","form_type":"4"}},{"id":1685351,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-05T16:00:17.000Z","date":"2024-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":50955,"price":0.4961,"value":25278.7755,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":443034,"source":{"system":"sec-edgar","filing":"0001209191-24-000970","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919124000970/doc4.xml","form_type":"4"}},{"id":1765086,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":65000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":65000,"derivative":{"exercise_price":0.31,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765085,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":12500,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":12500,"derivative":{"exercise_price":0.31,"expiration_date":"2023-07-28","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765084,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":165000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":165000,"derivative":{"exercise_price":0.31,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765083,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":2000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a \"Qualifying Termination\"); or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"25% of the Option Shares vested on February 21, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":2000,"derivative":{"exercise_price":0.31,"expiration_date":"2031-02-21","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765082,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":7000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a \"Qualifying Termination\"); or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the Option Shares vested on January 27, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":7000,"derivative":{"exercise_price":0.31,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765081,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":22000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a \"Qualifying Termination\"); or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option (the \"Option Shares\") are fully vested."}],"balance_after":12240,"derivative":{"exercise_price":0.31,"expiration_date":"2030-01-07","underlying":"Common Stock","underlying_shares":12240},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765080,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":0.96,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765079,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":0,"derivative":{"exercise_price":1.04,"expiration_date":"2023-07-28","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765078,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":165000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":1.94,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765077,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"25% of the Option Shares vested on February 21, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":7.48,"expiration_date":"2031-02-21","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765076,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the Option Shares vested on January 27, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":5.33,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765075,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option (the \"Option Shares\") are fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.13,"expiration_date":"2030-01-07","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765074,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":650000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":650000,"derivative":{"exercise_price":0.31,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765073,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":123750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":123750,"derivative":{"exercise_price":0.31,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":123750},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765072,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":637000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":637000,"derivative":{"exercise_price":0.31,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":637000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765071,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":750000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a \"Qualifying Termination\"); or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the Option Shares vested on February 11, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":750000,"derivative":{"exercise_price":0.31,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765070,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":66890,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a \"Qualifying Termination\"); or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option (the \"Option Shares\") are fully vested."}],"balance_after":66890,"derivative":{"exercise_price":0.31,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":66890},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765069,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a \"Qualifying Termination\"); or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option (the \"Option Shares\") are fully vested."}],"balance_after":100000,"derivative":{"exercise_price":0.31,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765068,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":650000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":0.96,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765067,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":123750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":0,"derivative":{"exercise_price":1.04,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":123750},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765066,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":637000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":1.94,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":637000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765065,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":750000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the Option Shares vested on February 11, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":7.05,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765064,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":66890,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option (the \"Option Shares\") are fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.33,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":66890},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1765063,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-10-04T17:00:34.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 7 and 8, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option (the \"Option Shares\") are fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.76,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-052019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052019/doc4.xml","form_type":"4"}},{"id":1835598,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-07-05T18:59:54.000Z","date":"2023-07-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":4007,"price":0.36,"value":1442.52,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":19911,"source":{"system":"sec-edgar","filing":"0001209191-23-041319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123041319/doc4.xml","form_type":"4"}},{"id":1835597,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-07-05T18:59:54.000Z","date":"2023-07-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":47992,"price":0.36,"value":17277.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":493989,"source":{"system":"sec-edgar","filing":"0001209191-23-041319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123041319/doc4.xml","form_type":"4"}},{"id":1918902,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-17T06:00:07.000Z","date":"2023-04-14","kind":"purchase","planned":false,"acquired":true,"shares":2250,"price":0.29,"value":652.5,"ownership":{"direct":false,"nature":"By Family Trust"},"balance_after":196544,"source":{"system":"sec-edgar","filing":"0001209191-23-024390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123024390/doc4.xml","form_type":"4"}},{"id":1918901,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-17T06:00:07.000Z","date":"2023-04-14","kind":"purchase","planned":false,"acquired":true,"shares":47750,"price":0.299,"value":14277.25,"ownership":{"direct":false,"nature":"By Family Trust"},"balance_after":194294,"source":{"system":"sec-edgar","filing":"0001209191-23-024390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123024390/doc4.xml","form_type":"4"}},{"id":1918900,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-17T06:00:07.000Z","date":"2023-04-13","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.29,"value":29000.0,"ownership":{"direct":false,"nature":"By Family Trust"},"balance_after":146544,"source":{"system":"sec-edgar","filing":"0001209191-23-024390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123024390/doc4.xml","form_type":"4"}},{"id":1992759,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-02-24T16:00:13.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":42196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 14, 2018, the recipient received a stock option to purchase 168,787 shares, which vest on the achievement of certain pre-established strategic milestones. The issuer's Compensation Committee determined that two such strategic milestones were achieved, resulting in the vesting of 42,196 shares subject to the stock option effective February 21, 2023. 21,098 shares subject to the option remain unvested."}],"balance_after":42196,"derivative":{"exercise_price":0.81,"expiration_date":"2028-11-14","underlying":"Common Stock","underlying_shares":42196},"source":{"system":"sec-edgar","filing":"0001209191-23-012657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123012657/doc4.xml","form_type":"4"}},{"id":1992758,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-02-24T16:00:13.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date."}],"balance_after":65000,"derivative":{"exercise_price":0.96,"expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-012657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123012657/doc4.xml","form_type":"4"}},{"id":1992757,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-02-24T16:00:13.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date."}],"balance_after":650000,"derivative":{"exercise_price":0.96,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001209191-23-012657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123012657/doc4.xml","form_type":"4"}},{"id":2062185,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-05T18:00:49.000Z","date":"2023-01-03","kind":"tax_withholding","acquired":false,"shares":1325,"price":1.02,"value":1351.5,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":23918,"source":{"system":"sec-edgar","filing":"0001209191-23-002033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123002033/doc4.xml","form_type":"4"}},{"id":2062184,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-05T18:00:49.000Z","date":"2023-01-03","kind":"tax_withholding","acquired":false,"shares":27793,"price":1.02,"value":28348.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":541981,"source":{"system":"sec-edgar","filing":"0001209191-23-002033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123002033/doc4.xml","form_type":"4"}},{"id":2198945,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2022-08-01T18:18:07.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One half of the shares subject to the stock options vest on July 3, 2023 and one half of the shares subject to the stock options vest on January 3, 2024, subject to the Recipient's continued employment or service with the Issuer on each such date. All of the shares subject to the stock options vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":12500,"derivative":{"exercise_price":1.04,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-22-043735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122043735/doc4.xml","form_type":"4"}},{"id":2198944,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2022-08-01T18:18:07.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":123750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One half of the shares subject to the stock options vest on July 3, 2023 and one half of the shares subject to the stock options vest on January 3, 2024, subject to the Recipient's continued employment or service with the Issuer on each such date. All of the shares subject to the stock options vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":123750,"derivative":{"exercise_price":1.04,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":123750},"source":{"system":"sec-edgar","filing":"0001209191-22-043735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122043735/doc4.xml","form_type":"4"}},{"id":2198943,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-08-01T18:18:07.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on July 3, 2023, and one half of the RSUs vest on January 3, 2024, subject to the Recipient's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":25243,"source":{"system":"sec-edgar","filing":"0001209191-22-043735","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122043735/doc4.xml","form_type":"4"}},{"id":2198942,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-08-01T18:18:07.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":185625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on July 3, 2023, and one half of the RSUs vest on January 3, 2024, subject to the Recipient's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":569774,"source":{"system":"sec-edgar","filing":"0001209191-22-043735","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122043735/doc4.xml","form_type":"4"}},{"id":2223042,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-23T16:30:25.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date."}],"balance_after":27500,"derivative":{"exercise_price":1.95,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001209191-22-038881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919122038881/doc4.xml","form_type":"4"}},{"id":2341625,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T19:16:42.000Z","date":"2022-03-07","kind":"disposition_to_issuer","acquired":false,"shares":22000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":17.83,"expiration_date":"2031-05-26","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000899243-22-010312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010312/doc4.xml","form_type":"4"}},{"id":2341624,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T19:16:42.000Z","date":"2022-03-07","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":12.75,"expiration_date":"2027-05-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-010312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010312/doc4.xml","form_type":"4"}},{"id":2341623,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T19:16:42.000Z","date":"2022-03-07","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2026-07-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-010312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010312/doc4.xml","form_type":"4"}},{"id":2341622,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T19:16:42.000Z","date":"2022-03-07","kind":"disposition_to_issuer","acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":12.8,"expiration_date":"2025-06-17","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000899243-22-010312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010312/doc4.xml","form_type":"4"}},{"id":2341621,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T19:16:42.000Z","date":"2022-03-07","kind":"disposition_to_issuer","acquired":false,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":15.52,"expiration_date":"2024-05-20","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0000899243-22-010312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010312/doc4.xml","form_type":"4"}},{"id":2341620,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T19:16:42.000Z","date":"2022-03-07","kind":"disposition_to_issuer","acquired":false,"shares":9375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") with an exercise price less than $26.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an \"Out of the Money Option\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":24.56,"expiration_date":"2024-03-24","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0000899243-22-010312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010312/doc4.xml","form_type":"4"}},{"id":2341619,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-09T19:16:42.000Z","date":"2022-03-07","kind":"other","acquired":false,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 18, 2022, (the \"Merger Agreement\"), among UCB S.A., a societe anonyme formed under the laws of Belgium (\"Parent\"), Zinc Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (\"Purchaser\") and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of March 7, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $26.00 in cash (the \"Cash Amount\") plus a contingent value right (\"CVR\"), which CVR represents the right to receive a contingent payment of $2.00 which amount will become payable, if at all, if a specified milestone is achieved on or prior to December 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 18, 2022, (the \"Merger Agreement\"), among UCB S.A., a societe anonyme formed under the laws of Belgium (\"Parent\"), Zinc Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (\"Purchaser\") and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of March 7, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $26.00 in cash (the \"Cash Amount\") plus a contingent value right (\"CVR\"), which CVR represents the right to receive a contingent payment of $2.00 which amount will become payable, if at all, if a specified milestone is achieved on or prior to December 31, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-010312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000089924322010312/doc4.xml","form_type":"4"}},{"id":2420975,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-31T16:00:12.000Z","date":"2022-01-27","kind":"purchase","acquired":true,"shares":25000,"price":1.6832,"value":42080.0,"ownership":{"direct":false,"nature":"By Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.66 to $1.85. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above."}],"balance_after":46544,"source":{"system":"sec-edgar","filing":"0001209191-22-005556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122005556/doc4.xml","form_type":"4"}},{"id":2427601,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2022-01-24T16:14:57.000Z","date":"2022-01-20","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in 36 equal monthly installments over the three-year period thereafter, subject to the Recipient's continued employment or service with the Issuer on each such date."}],"balance_after":165000,"derivative":{"exercise_price":1.94,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001209191-22-004594","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122004594/doc4.xml","form_type":"4"}},{"id":2427600,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2022-01-24T16:14:57.000Z","date":"2022-01-20","kind":"grant","acquired":true,"shares":637000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in 36 equal monthly installments over the three-year period thereafter, subject to the Recipient's continued employment or service with the Issuer on each such date."}],"balance_after":637000,"derivative":{"exercise_price":1.94,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":637000},"source":{"system":"sec-edgar","filing":"0001209191-22-004594","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122004594/doc4.xml","form_type":"4"}},{"id":2443362,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-05T19:00:35.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":6793,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on January 3, 2023, one quarter of the RSUs vest on July 3, 2023, and one quarter of the RSUs vest on January 3, 2024, subject to the Recipient's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":6793,"source":{"system":"sec-edgar","filing":"0001209191-22-001974","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122001974/doc4.xml","form_type":"4"}},{"id":2443361,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-05T19:00:35.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":128557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on January 3, 2023, one quarter of the RSUs vest on July 3, 2023, and one quarter of the RSUs vest on January 3, 2024, subject to the Recipient's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":384149,"source":{"system":"sec-edgar","filing":"0001209191-22-001974","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122001974/doc4.xml","form_type":"4"}},{"id":2655796,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-24T17:00:12.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date."}],"balance_after":17500,"derivative":{"exercise_price":2.18,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-21-043069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919121043069/doc4.xml","form_type":"4"}},{"id":2691046,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-28T20:03:20.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on May 27, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholders, and shall become exercisable with respect to the underlying shares of common stock in a series of twelve (12) successive, equal monthly installments on each monthly anniversary of the grant date, such that the option shall be fully vested twelve months following the date of grant, subject to the Reporting Person's continuing service on the Board of the Issuer through such dates."}],"balance_after":22000,"derivative":{"exercise_price":17.83,"expiration_date":"2031-05-27","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001375151-21-000066","document":"wf-form4_162224658464064.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515121000066/wf-form4_162224658464064.xml","form_type":"4"}},{"id":2776115,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2021-03-22T16:00:09.000Z","date":"2021-03-18","kind":"grant","acquired":true,"shares":63295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 14, 2018, the reporting person was granted an award of stock options that vest upon the achievement of certain pre-established strategic milestones. On March 18, 2021, the Compensation Committee of the Issuers board of directors determined that certain of the strategic milestones have been achieved, resulting in the vesting of options to purchase 63,295 shares of the Issuers common stock."}],"balance_after":105492,"derivative":{"exercise_price":0.81,"expiration_date":"2028-11-14","underlying":"Common Stock","underlying_shares":63295},"source":{"system":"sec-edgar","filing":"0001209191-21-022309","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919121022309/doc4.xml","form_type":"4"}},{"id":2838783,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-02-23T20:12:36.000Z","date":"2021-02-21","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options generally vest as follows: 25% of the total number of shares subject to the options shall vest on the first anniversary of the vesting commencement date and 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of the vesting commencement date thereafter, subject to the option recipient's continuous service to the Corporation on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the vesting commencement date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"2,000 Stock Options granted to Mary Breitmeyer with a February 21, 2021 transaction date."}],"balance_after":2000,"derivative":{"exercise_price":7.48,"expiration_date":"2031-02-21","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-21-013507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919121013507/doc4.xml","form_type":"4"}},{"id":2838782,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-02-23T20:12:36.000Z","date":"2021-01-27","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options generally vest as follows: 25% of the total number of shares subject to the options shall vest on the first anniversary of the vesting commencement date and 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of the vesting commencement date thereafter, subject to the option recipient's continuous service to the Corporation on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the vesting commencement date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"7,000 Stock Options granted to Mary Breitmeyer with a January 27, 2021 transaction date."}],"balance_after":7000,"derivative":{"exercise_price":5.33,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001209191-21-013507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919121013507/doc4.xml","form_type":"4"}},{"id":2858668,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-02-16T18:00:50.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Persons continued employment or service with the Issuer on each such date."}],"balance_after":750000,"derivative":{"exercise_price":7.05,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001209191-21-010906","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919121010906/doc4.xml","form_type":"4"}},{"id":3072374,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2020-07-31T21:05:46.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 reported the acquisition of the Stock Options in the \"D\" column of Column 5.  This amendment is being filed to correctly report the acquisition of the Stock Options in the \"A\" column of Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Persons continued employment or service with the Issuer on each such date."}],"balance_after":100000,"derivative":{"exercise_price":5.76,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-20-044374","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919120044374/doc4a.xml","form_type":"4/A","original_submission_date":"2019-09-16"}},{"id":3072369,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2020-07-31T21:05:22.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":66890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 reported the acquisition of the Stock Options in the \"D\" column of Column 5.  This amendment is being filed to correctly report the acquisition of the Stock Options in the \"A\" column of Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested on grant date."}],"balance_after":66890,"derivative":{"exercise_price":3.33,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":66890},"source":{"system":"sec-edgar","filing":"0001209191-20-044362","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919120044362/doc4a.xml","form_type":"4/A","original_submission_date":"2020-03-18"}},{"id":3072367,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2020-07-31T21:05:18.000Z","date":"2020-01-07","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 reported the acquisition of the Stock Options in the \"D\" column of Column 5.  This amendment is being filed to correctly report the acquisition of the Stock Options in the \"A\" column of Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options generally vest as follows: 25% of the total number of shares subject to the options shall vest on the first anniversary of the vesting commencement date and 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of the vesting commencement date thereafter, subject to the option recipient's continuous service to the Corporation on each such vesting date, so that the options shall be fully vested on the forth anniversary of the vesting commencement date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"22,000 Stock Options granted to Mary Breitmeyer with a January 7,2020 transaction date ."}],"balance_after":22000,"derivative":{"exercise_price":22000,"expiration_date":"2030-01-07","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-20-044360","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919120044360/doc4a.xml","form_type":"4/A","original_submission_date":"2020-01-09"}},{"id":3097474,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-29T21:12:23.000Z","date":"2020-05-29","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on May 29, 2020, the date of the Company's 2020 Annual Meeting of Stockholders, and vests in twelve (12) equal monthly installments from the grant date, such that the option is fully vested on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Company on each vesting date."}],"balance_after":13000,"derivative":{"exercise_price":29.13,"expiration_date":"2030-05-29","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001375151-20-000111","document":"wf-form4_159347952805219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515120000111/wf-form4_159347952805219.xml","form_type":"4"}},{"id":3099746,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-25T17:07:44.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date."}],"balance_after":17500,"derivative":{"exercise_price":3.56,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-20-038945","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919120038945/doc4.xml","form_type":"4"}},{"id":3202156,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2020-03-18T18:52:21.000Z","date":"2020-03-17","kind":"grant","acquired":false,"shares":66890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested on grant date."}],"balance_after":66890,"derivative":{"exercise_price":3.33,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":66890},"source":{"system":"sec-edgar","filing":"0001209191-20-020095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919120020095/doc4.xml","form_type":"4"}},{"id":3314394,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2020-01-09T16:00:12.000Z","date":"2020-01-07","kind":"grant","acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options generally vest as follows: 25% of the total number of shares subject to the options shall vest on the first anniversary of the vesting commencement date and 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of the vesting commencement date thereafter, subject to the option recipient's continuous service to the Corporation on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the vesting commencement date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"22,000 Stock Options granted to Mary Breitmeyer with a January 7, 2020 transaction date."}],"balance_after":22000,"derivative":{"exercise_price":4.13,"expiration_date":"2030-01-07","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-20-002701","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919120002701/doc4.xml","form_type":"4"}},{"id":3336629,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-18T16:07:37.000Z","date":"2019-12-16","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on July 13, 2016 and vests in a series of twelve (12) successive, equal monthly installments beginning on August 1, 2016, subject to the Reporting Person's continued service to the Company on each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":8.99,"expiration_date":"2026-07-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001375151-19-000134","document":"wf-form4_157670322671332.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515119000134/wf-form4_157670322671332.xml","form_type":"4"}},{"id":3336628,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-18T16:07:37.000Z","date":"2019-12-16","kind":"sale","acquired":false,"shares":5000,"price":50,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":1250,"source":{"system":"sec-edgar","filing":"0001375151-19-000134","document":"wf-form4_157670322671332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515119000134/wf-form4_157670322671332.xml","form_type":"4"}},{"id":3336627,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-18T16:07:37.000Z","date":"2019-12-16","kind":"exercise","acquired":true,"shares":5000,"price":8.99,"value":44950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001375151-19-000134","document":"wf-form4_157670322671332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515119000134/wf-form4_157670322671332.xml","form_type":"4"}},{"id":3357260,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-27T16:13:38.000Z","date":"2019-11-25","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on July 13, 2016 and vests in a series of twelve (12) successive, equal monthly installments beginning on August 1, 2016, subject to the Reporting Person's continued service to the Company on each vesting date."}],"balance_after":15000,"derivative":{"exercise_price":8.99,"expiration_date":"2026-07-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001375151-19-000129","document":"wf-form4_157488919988967.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515119000129/wf-form4_157488919988967.xml","form_type":"4"}},{"id":3357259,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-27T16:13:38.000Z","date":"2019-11-25","kind":"sale","acquired":false,"shares":5000,"price":50,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":1250,"source":{"system":"sec-edgar","filing":"0001375151-19-000129","document":"wf-form4_157488919988967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515119000129/wf-form4_157488919988967.xml","form_type":"4"}},{"id":3357258,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-27T16:13:38.000Z","date":"2019-11-25","kind":"exercise","acquired":true,"shares":5000,"price":8.99,"value":44950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001375151-19-000129","document":"wf-form4_157488919988967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515119000129/wf-form4_157488919988967.xml","form_type":"4"}},{"id":3413739,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2019-09-16T17:37:52.000Z","date":"2019-09-12","kind":"grant","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Persons continued employment or service with the Issuer on each such date."}],"balance_after":100000,"derivative":{"exercise_price":5.76,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-049688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919119049688/doc4.xml","form_type":"4"}},{"id":3482291,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Options","published_at":"2019-06-20T16:34:24.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":42196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 14, 2018, the reporting person was granted an award of stock options that vest upon the achievement of certain pre-established strategic milestones. On June 18, 2019, the Compensation Committee of the Issuer's board of directors determined that one such strategic milestone had been achieved, resulting in the vesting of options to purchase 42,196 shares of the Issuer's common stock."}],"balance_after":42196,"derivative":{"exercise_price":0.81,"expiration_date":"2028-11-14","underlying":"Common Stock","underlying_shares":42196},"source":{"system":"sec-edgar","filing":"0000899243-19-017661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000089924319017661/doc4.xml","form_type":"4"}},{"id":3491402,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-13T17:03:08.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date."}],"balance_after":17500,"derivative":{"exercise_price":2.35,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-19-036836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919119036836/doc4.xml","form_type":"4"}},{"id":3493918,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Warrants","published_at":"2019-06-11T18:31:49.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":733,"ownership":{"direct":false,"nature":"By family trust."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The warrants are currently exercisable."}],"balance_after":733,"derivative":{"exercise_price":6.13,"expiration_date":"2022-09-12","underlying":"Common Stock","underlying_shares":733},"source":{"system":"sec-edgar","filing":"0000899243-19-016474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000089924319016474/doc4.xml","form_type":"4"}},{"id":3493917,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Options","published_at":"2019-06-11T18:31:49.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":1467,"ownership":{"direct":false,"nature":"By spouse."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is currently vested with respect to 826 shares. The remaining shares subject to the option will vest in equal monthly installments until February 1, 2021."}],"balance_after":1467,"derivative":{"exercise_price":0.68,"expiration_date":"2027-04-12","underlying":"Common Stock","underlying_shares":1467},"source":{"system":"sec-edgar","filing":"0000899243-19-016474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000089924319016474/doc4.xml","form_type":"4"}},{"id":3493916,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Options","published_at":"2019-06-11T18:31:49.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":117417,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is currently vested with respect to 110,079 shares. The remaining shares subject to the option will vest in three equal monthly installments beginning on June 30, 2019."}],"balance_after":117417,"derivative":{"exercise_price":0.68,"expiration_date":"2025-08-30","underlying":"Common Stock","underlying_shares":117417},"source":{"system":"sec-edgar","filing":"0000899243-19-016474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000089924319016474/doc4.xml","form_type":"4"}},{"id":3493915,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2019-06-11T18:31:49.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":21544,"ownership":{"direct":false,"nature":"By family trust."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."}],"balance_after":21544,"source":{"system":"sec-edgar","filing":"0000899243-19-016474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000089924319016474/doc4.xml","form_type":"4"}},{"id":3493914,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2019-06-11T18:31:49.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":733,"ownership":{"direct":false,"nature":"By child."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."}],"balance_after":733,"source":{"system":"sec-edgar","filing":"0000899243-19-016474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000089924319016474/doc4.xml","form_type":"4"}},{"id":3493913,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2019-06-11T18:31:49.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":255591,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."}],"balance_after":255591,"source":{"system":"sec-edgar","filing":"0000899243-19-016474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000089924319016474/doc4.xml","form_type":"4"}},{"id":3510153,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-28T16:05:48.000Z","date":"2019-05-22","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on May 22, 2019, the date of the Company's 2019 Annual Meeting of Stockholders, and vests in twelve (12) equal monthly installments from the grant date, such that the option is fully vested on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Company on each vesting date."}],"balance_after":13000,"derivative":{"exercise_price":39.02,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001375151-19-000078","document":"wf-form4_155907393362190.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515119000078/wf-form4_155907393362190.xml","form_type":"4"}},{"id":3887177,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-20T19:40:50.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on each anniversary of the date of grant, provided that the Reporting Person remains a service provider through each such date."}],"balance_after":35000,"derivative":{"exercise_price":4.45,"expiration_date":"2028-06-18","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-18-038879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919118038879/doc4.xml","form_type":"4"}},{"id":3918478,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-24T18:10:44.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Annual director stock option grant under the issuer's incentive compensation plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on May 23, 2018, the date of the Company's Annual Meeting of Stockholders, and vests in twelve (12) equal monthly installments from the grant date such that the option is fully vested on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Company on each vesting date."}],"balance_after":15000,"derivative":{"exercise_price":41.68,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001375151-18-000043","document":"wf-form4_152719978199127.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515118000043/wf-form4_152719978199127.xml","form_type":"4"}},{"id":4307980,"issuer":{"id":129305,"kind":"organization","name":"ZOGENIX, INC.","symbol":"ZGNX"},"owners":[{"id":29984,"kind":"person","name":"BREITMEYER JAMES B","position":1,"cik":"0001244823","reported_name":"BREITMEYER JAMES B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-23T19:02:21.000Z","date":"2017-05-23","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Annual director stock option grant under the issuer's incentive compensation plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on May 23, 2017, the date of the Company's Annual Meeting of Stockholders, and vests in a series of twelve (12) successive, equal monthly installments beginning on June 23, 2017, subject to the reporting person's continued service to the Company on each vesting date."}],"balance_after":20000,"derivative":{"exercise_price":12.75,"expiration_date":"2027-05-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001375151-17-000036","document":"wf-form4_149558052599583.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375151/000137515117000036/wf-form4_149558052599583.xml","form_type":"4"}}]}